IMNM

Immunome's stock price has experienced significant movements over the past six months, with a 159.21% increase in share price over the past year. Key events include positive topline results for the Phase 3 RINGSIDE trial of varegacestat in December 2025, a financing round raising $432.4 million, an upsized underwritten public offering generating $172.5 million in January 2026, and a biotech-focused fund adding $12 million to its Immunome investment in February 2026. In March 2026, Immunome reported its full-year 2025 financial results, with a net loss of $212.4 million. In April 2026, Immunome announced the submission of an NDA to the FDA for varegacestat and data from the Phase 3 RINGSIDE trial was selected for oral presentation at the 2026 ASCO Annual Meeting. In May 2026, Immunome is expected to report Q1 2026 results.